Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Acute Mountain Sickness
Interventions: Prochlorperazine Maleate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Evergreen, Colorado

Conditions: Skin Infection, Bacterial Infection
Interventions: Daptomycin, Brilacidin; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 1 more

Conditions: Major Depressive Disorder
Interventions: Low Dose Fish Oil, High Dose Fish Oil; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Diclofenac Sodium Gel; Drug
Lead sponsor: Amzell; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Chronic Lower Back Pain (CLBP)
Interventions: Within-subject test of blinded study medications (Placebo, Hydromorphone, Gabapentin); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Shigellosis
Interventions: Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 8 Months to 50 Years
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 0
States / cities: Not listed

Conditions: Myeloid Diseases
Interventions: DFV890; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Stanford, California • Tampa, Florida • Chicago, Illinois + 7 more

Conditions: Gout
Interventions: High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose); Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Healthy Participants
Interventions: PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Formulation Bridging, Food Effect
Interventions: PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Hollywood, Florida • Miami, Florida

Conditions: Permanent Chemotherapy-induced Alopecia
Interventions: oral minoxidil; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury
Interventions: 0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Facet Joints; Degeneration, Back Pain, Facet Joint Pain
Interventions: Alocyte low dose, Alocyte medium dose, Alocyte high dose; Drug
Lead sponsor: Alimorad Farshchian; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more

Conditions: Prostate Cancer
Interventions: Docetaxel, ADT, Abiraterone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cognitive Function, Video Gamers
Interventions: Phaeosol low dose, Phaeosol high dose, Placebo; Dietary Supplement
Lead sponsor: Microphyt; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Verruca Vulgaris, Warts, Common Wart
Interventions: VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 9 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more

Conditions: Low Back Pain
Interventions: Ibuprofen, Osteopathic manipulative treatment; Drug · Procedure
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Interventions: Sitagliptin; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Non-Small Cell Lung Cancer
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more

Conditions: Ductal Carcinoma in Situ
Interventions: Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen; Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 30
States / cities: Berkeley, California • Duarte, California • Irvine, California + 23 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Granada Hills, California • Northridge, California • Torrance, California + 5 more

Search by objective public record fields.

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

Mechanistic Evaluation of Polypharmacy Effects for Pain

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

MPC-004 for the Treatment of an Acute Gout Flare

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

Fluid Chloride and AKI in Cardiopulmonary Bypass

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Efficacy of a Microalgae Extract PhaeoSOL Combined With Natural Stimulant on Cognitive Function and Gaming Performance of Video Gamers

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Acute Low Back Pain in the Emergency Department Treated With Osteopathic Manipulative Treatment Versus NSAIDs

Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Study of Verinurad in Heart Failure With Preserved Ejection Fraction